Case for Consideration: A 30-year-old HIV-positive man with psoriasis
Abstract
You are seeing a 30-year-old man with a history of established psoriasis in your outpatient dermatology clinic. The patient has well-controlled human immunodeficiency virus (HIV) and he takes a new antiretroviral (ARV) medication, Biktarvy®. The patient’s HIV in the blood is undetectable and his CD4 T-cell count is normal. His health is otherwise good. During the clinical workup, he mentions that his partner is HIV-negative and is on pre-exposure prophylaxis (PrEP) medication and has developed brown facial spots and is wondering if the PrEP medication may have caused this and also wants to see a dermatologist.
The patient starts on combination calcipotriene / betamethasone dipropionate foam and considers phototherapy. Upon reviewing the data on Biktarvy®, you become aware that it causes “rash” and wonder about interactions with acitretin, cyclosporine, or methotrexate. Biktarvy® contains bictegravir, emtricitabine and tenofovir alenamide. It does not contain ritonavir.
HIV and its treatment have changed significantly over the past 30 years. The virus can be fully suppressed with antiretroviral therapy (ARV), formerly known as highly active antiretroviral therapy (HAART). If ARVs are accessible and started early, collaborative cohort studies across Europe and North America demonstrate improved survival & life expectancy. There are now no threshold levels for initiation of ARVs based on CD4 T-cell count or viral load, if the ARVs are accessible to the patient. Treatment is generally recommended after diagnosis of HIV.
References
Bosamiya SS. The immune reconstitution inflammatory syndrome. Indian J Dermatol. 2011;56(5):476–479. doi:10.4103/0019-5154.87114
Cohen MS, et al. Preexposure prophylaxis for HIV–where do we go from here? N Engl J Med. 2012 Aug 2;367(5):459-61.
Thigpen MC, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012 Aug 2;367(5):423-34.
Grant RM, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010 Dec 30;363(27):2587-99.
Cohen MS, et al. “Prevention of HIV-1 infection with early antiretroviral therapy.” New England journal of medicine. 2011;365(6):493-505.
Hill A, et al. “Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?” Journal of virus eradication. 2018;4(2):72.
Kauppinen KJ, Kivelä P, Sutinen J. “Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting.” AIDS patient care and STDs. 2019 Dec;33(12):500-506.
Hoosen K, Mosam A, Dlova NC, Grayson W. An Update on Adverse Cutaneous Drug Reactions in HIV/AIDS. Dermatopathology (Basel). 2019;6(2):111–125.
Introcaso CE, et al. Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors. J Am Acad J Am Acad Dermatol. 2010 Oct;63(4):563-9.
Introcaso CE, et al. Cutaneous toxicities of antiretroviral therapy for HIV: part II. Nonnucleoside reverse transcriptase inhibitors, entry and fusion inhibitors, integrase inhibitors, and immune reconstitution syndrome. J Am Acad Dermatol. 2010 Oct;63(4):563-9.
https://www.aids.gov.hk/ice/ice201604.pdf
De Waal R, Cohen K, Maartens G. Systematic review of antiretroviral-associated lipodystrophy: lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. PLoS One. 2013;8(5):e63623.
Yombi JC, Maiter D, Belkhir L, et al. Iatrogenic Cushing’s syndrome and secondary adrenal insufficiency after a single intra-articular administration of triamcinolone acetonide in HIV-infected patients treated with ritonavir. Clin Rheumatol. 2008 Dec;27 Suppl 2:S79-82.
Schwarze-Zander C, et al. Triamcinolone and ritonavir leading to drug-induced Cushing syndrome and adrenal suppression: description of a new case and review of the literature. Infection. 2013 Dec;41(6):1183-7. doi: 10.1007/s15010-013-0506-z. Epub 2013 Jul 20.
Levine D, et al. Iatrogenic Cushing syndrome after a single intramuscular corticosteroid injection and concomitant protease inhibitor therapy. J Am Acad Dermatol. 2011 Oct;65(4):877-878.
Vogel M, et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transpl. 2004 Jul;10(7):939-44.
Lewis J, et al. A case of iatrogenic adrenal suppression after co-administration of cobicistat and fluticasone nasal drops. AIDS. 2014; 28: 2633–39.
Buccheri L, Katchen BR, Karter AJ, Cohen SR. Acitretin Therapy Is Effective for Psoriasis Associated With Human Immunodeficiency Virus Infection. Arch Dermatol. 1997;133(6):711–715. doi:10.1001/archderm.1997.03890420043005
Masson C, Chennebault JM, Leclech C. Is HIV infection contraindication to the use of methotrexate in psoriatic arthritis? J Rheumatol. 1995;22:2191.
Maurer TA, Zackheim HS, Tuffanelli L, et al. The use of methotrexatefor treatment of psoriasis in patients with HIV infection. J Am AcadDermatol. 1994;31:372-375.
Duvic M, Johnson TM, Rapini RP, et al. Acquired immunodeficiencysyndrome-associated psoriasis and Reiter’s syndrome. Arch Dermatol. 1987;123:1622-1632.
Nakamura M, et al. Psoriasis treatment in HIV-positive patients: a systematic review of systemic immunosuppressive therapies. Cutis. 2018 Jan;101(1):38;42;56.
Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017 Aug;4(8):e349-e356.
